Treatment as prevention among injecting drug users; extrapolating from the Amsterdam cohort study

被引:7
|
作者
de Vos, Anneke S. [1 ]
Prins, Maria [2 ,3 ]
Coutinho, Roel A. [1 ,4 ]
van der Helm, Jannie J. [2 ]
Kretzschmar, Mirjam E. E. [1 ,4 ]
机构
[1] Univ Med Ctr Utrecht, Julius Ctr, Utrecht, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Publ Hlth Serv Amsterdam, Cluster Infect Dis, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, CINIMA, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands
[4] RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands
关键词
HIV; injecting drug use; risk heterogeneity; test and treat; treatment as prevention; HEPATITIS-C VIRUS; ANTIRETROVIRAL THERAPY; HIV; TRANSMISSION; INFECTION; ADHERENCE; HAART; ELIMINATION; RISK;
D O I
10.1097/QAD.0000000000000190
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective:To determine the potential of treatment as prevention for reducing HIV incidence among injecting drug users (IDU).Methods:Transmission dynamics of HIV as influenced by cART uptake and demographic changes were studied using an individual-based model. Parameters were based on data of the Amsterdam Cohort Study, and counterfactual treatment scenarios were examined for this city. Demography of the modeled population was also varied to allow for more general conclusions.Results:We estimated that over the complete HIV epidemic among IDU in Amsterdam the historic use of cART has led to only 2% less incidence. As individuals were treated from low CD4(+) cell counts, their decreased infectiousness was offset by increased infectious lifetime. Large reduction in incidence could result from a test and immediate treat strategy, with elimination of HIV occurring when the average time from infection to starting treatment was less than 2 months. However, substantial proportions of new infections were prevented only if the test and treat intervention was implemented within the first few years after HIV-epidemic onset, especially for a declining IDU population. Ignoring heterogeneity in risk-behavior led to overly optimistic expectations of the prevention effects of treatment. In general, treatment led to much greater reduction in incidence compared with stopping HIV-infected IDU from lending out syringes.Conclusion:A test and immediate treat strategy for HIV among IDU could lead to great reductions in incidence. To fully eliminate the spread of HIV, treatment as prevention should be combined with other interventions, with behavioral intervention directed at those not yet HIV infected.
引用
收藏
页码:911 / 918
页数:8
相关论文
共 50 条
  • [41] Global overview of injecting drug use and HIV infection among injecting drug users
    Aceijas, C
    Stimson, GV
    Hickman, M
    Rhodes, T
    AIDS, 2004, 18 (17) : 2295 - 2303
  • [42] Retrospective cohort study examining incidence of HIV and hepatitis C infection among injecting drug users in Dublin
    Smyth, BP
    O'Connor, JJ
    Barry, J
    Keenan, E
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2003, 57 (04) : 310 - 311
  • [43] Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study
    Judd, A
    Hickman, M
    Jones, S
    McDonald, T
    Parry, JV
    Stimson, GV
    Hall, AJ
    BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7481): : 24 - 25
  • [44] Injecting drug users who want treatment
    Zule, WA
    Desmond, DP
    Vogtsberger, KN
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 1997, 23 (04): : 507 - 522
  • [45] HIV treatment as prevention among injection drug users
    Wood, Evan
    Milloy, Michael John
    Montaner, Julio S. G.
    CURRENT OPINION IN HIV AND AIDS, 2012, 7 (02) : 151 - 156
  • [46] Evidence for Action: A critical tool for guiding policies and programmes for HIV prevention, treatment and care among injecting drug users
    Ball, A
    Weiler, GA
    Beg, M
    Doupe, A
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2005, 16 : S1 - S6
  • [47] MODELLING THE UTILITY OF ANTIVIRAL TREATMENT FOR PRIMARY PREVENTION OF HEPATITIS C INFECTION AMONG INJECTING DRUG USERS IN VICTORIA, AUSTRALIA
    Hellard, Margaret
    Jenkinson, Rebecca
    Higgs, Peter
    Stoove, Mark
    Sacks-Davis, Rachel
    Gold, Judy
    Hickman, Matthew
    Vickerman, Peter
    Martin, Natasha K.
    HEPATOLOGY, 2011, 54 : 1194A - 1194A
  • [48] Understanding the context of risk practices among injecting drug users: Implications for hepatitis C prevention
    Habib, SE
    AUSTRALIAN JOURNAL OF SOCIAL ISSUES, 2003, 38 (01) : 1 - 17
  • [49] Harm Reduction and HIV-Prevention among Injecting Drug Users in Australia: An International Comparison
    Sendziuk, Paul
    CANADIAN BULLETIN OF MEDICAL HISTORY, 2007, 24 (01): : 113 - 129
  • [50] Mathilde Krim, amfAR, and the prevention of HIV infection among injecting drug users: A brief history
    Des Jarlais, Don C.
    AIDS PATIENT CARE AND STDS, 2006, 20 (07) : 467 - 471